Mesik explains that the supplement will be used for the following:
“Mild Cognitive Impairment (MCI) due to Alzheimer’s Disease (AD) is a clinical stage of AD that precedes the onset of dementia, making it an opportune stage for both elucidating early consequences of AD on neural function as well as identifying novel neural markers of AD that are reliable and affordable. The present proposal will address both goals by using non-invasive electroencephalographic (EEG) measurements to characterize how the processing of acoustics and linguistic features of continuous speech is affected in MCI with AD biomarkers and to assess whether these measures can reliably distinguish participants with and without MCI. These results will represent an initial step towards the longer-term goals of developing more reliable measures of neural function in AD that can be used for tracking disease progression and evaluation of the effects of novel clinical interventions.”
Juraj Mesik, PhD, research assistant professor and member of the Auditory Perception and Cognition Lab in the Department of Psychology at the University of Minnesota.